First a global investment fund, then one multinational pharma firm, then other international businesses are making efforts to split off their subsidiaries in China from global operations, in moves seemingly designed to buffer the operations from rising global geopolitical tensions.
UK-based drug maker AstraZeneca PLC is reportedly considering separating its Chinese business and registering it as an independent entity in Hong Kong, followed by a potential public listing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?